BIOPHARMA INNOVATION FACES NEW CHALLENGES AND PRESENTS NEW SOLUTIONS IN 2015

2014

has been a banner year for most all things healthcare.

THE MARKET & INDUSTRY



NEW DRUG APPROVALS

BIOTECH* +25%



M&A³ \$250 BILLION



IPO⁴
78
COMPANIES

2015

a changing biopharma landscape presents opportunities to further develop innovative medicines for patients.



THE CHALLENGE

\$2.6 BILLION

TO BRING A NEW TREATMENT TO MARKET

Healthcare budgets are shrinking and the industry is seeing an increased focus on cost-cutting in the short-term.

ASTELLAS' COMMITMENT TO DEVELOPING INNOVATIVE THERAPIES

R&D



Focus on innovative drug development and R&D, where 40% of drug approvals in the last decade have been first-in-class treatments.⁶ **PARTNERING**



Further collaborate with academia, government agencies and other biopharmaceutical companies to enhance innovation.

VALUE



Maximize the value of new medicines for patients by ensuring care is affordable over the long-term.

SCIENTIFIC INNOVATION



Spark biopharma innovation with the best science and best talent in a new era of precision and personalized medicine.

- 3 (http://www.ft.com/intl/cms/s/0/f742b876-8aa3-11e4-8e24-00144feabdc0.html?siteedition=uk#axzz3NBkSiSJv)
- 4 (h(http://www.orovillemr.com/business/20141224/biz-break-biotech -ipos-surge-in-silicon-valley-nationwide)
- 5 (http://csdd.tufts.edu/news/complete_story/pr_tufts_csdd_2014_cost_study)
- 6 (http://content.healthaffairs.org/content/32/8/1433.abstract)



^{1 (}http://bigstory.ap.org/article/e85c9213414f40f98fea7196a6a2dba5/fda-drug-approvals-reached-18-year-high-2014) 2 (http://money.usnews.com/funds/etfs/rankings/health-biotechnology-funds)

BIOPHARMA INNOVATION FACES NEW CHALLENGES AND PRESENTS NEW SOLUTIONS IN 2015

2014
has been a banner
year for most all

has been a banner year for most all things healthcare.

2015
a changing biopharma landscape presents opportunities to further develop innovative



medicines for

patients.

THE MARKET & INDUSTRY









THE CHALLENGE

\$2.6
BILLION
TO BRING A NEW
TREATMENT TO MARKET

Healthcare budgets are shrinking and the industry is seeing an increased focus on cost-cutting in the short-term.

ASTELLAS' COMMITMENT TO DEVELOPING INNOVATIVE THERAPIES

RESEARCH & DEVELOPMENT



Focus on innovative drug development and R&D, where 40% of drug approvals in the last decade have been first-in-class treatments.⁶

PARTNERING



Further collaborate with academia, government agencies and other biopharmaceutical companies to enhance innovation.

VALUE



Maximize the value of new medicines for patients by ensuring care is affordable over the long-term.

SCIENTIFIC INNOVATION



Spark biopharma innovation with the best science and best talent in a new era of precision and personalized medicine.

- 1 (http://bigstory.ap.org/article/e85c9213414f40f98fea7196a6a2dba5/fda-drug-approvals-reached-18-year-high-2014)
 2 (http://money.usnews.com/funds/etfs/rankings/health-biotechnology-funds)
- 3 (http://www.ft.com/intl/cms/s/0/f742b876-8aa3-11e4-8e24-00144feabdc0.html?siteedition=uk#axzz3NBkSjSJv)
- $\textcolor{red}{\textbf{4}} (h (http://www.orovillemr.com/business/20141224/biz-break-biotech-ipos-surge-in-silicon-valley-nationwide) \\$
- 5 (http://csdd.tufts.edu/news/complete_story/pr_tufts_csdd_2014_cost_study)
- 6 (http://content.healthaffairs.org/content/32/8/1433.abstract)

